About IASO

Company Overview

10 +

Innovative therapies
in development

100 +

Clinical centers
participating in trials

1000 +

Patients treated
in clinical studies

1 +

Approved CAR-T Therapy

300 +

Researchers
and scientists

IASO Bio is a commercial-stage biopharmaceutical company focused on developing innovative cell therapies and biologics for hematologic malignancies and autoimmune diseases.

Our fully integrated platforms span the entire product lifecycle—from discovery and clinical development to manufacturing and commercialization—bringing transformative therapies to patients worldwide.

Our portfolio includes ten therapeutic programs, led by Equecabtagene Autoleucel (eque-cel), a BCMA-targeted CAR-T therapy approved in China for relapsed or refractory multiple myeloma.

Our Culture

Mission

Making innovative therapies the backbone of patient cure

Vision

Bringing The Hope Of Cure To
Patients Through Innovative
Biotherapies

Values

Committed To Patients
Unwavering Resilience
Relentless Pioneering
Engaged Collaboration

Spirit

Innovation
Excellence
Responsibility
Cooperation
Efficiency

From a Nanjing laboratory to patients across the world

Since 2017, IASO Bio has grown from a single research lab into a global cell-therapy company — carrying CAR-T innovation from China to patients on three continents.

IASO global operating footprint — clinical, manufacturing and patient-access network across Asia-Pacific, North America and Latin America — 7markets reached4R&D & office centers100+clinical centers

Eight years, three chapters of growth

Global access expansion

2025

Global commercialization progress

Fucaso included in the national commercial insurance list
Eque-cel BLA approved in Hong Kong China
IASO Bio partnered with Korea's GC Cell
Eque-cel received CTN approval in Japan for r/r MM
Completed Series C2 financing and raised RMB215 million

2024

Autoimmune indications expanded

Fucaso achieved cross-border supply
Eque-cel received FDA IND approval for SLE and LN
Eque-cel received FDA IND approval for MG and MS
IASO782 received NMPA IND approval for SLE
Strategic collaboration with Innovent deepened

Clinical & regulatory acceleration

2023

Eque-cel approved by NMPA

Eque-cel BLA for r/r MM approved by the NMPA
IASO782 received IND approvals from U.S. FDA and NMPA
Research collaboration established with Umoja Biopharma
Company converted into a joint stock company
Completed Series C1 financing and raised RMB430 million

2022

Manufacturing capability established

Nanjing manufacturing base granted Drug Manufacturing License
Eque-cel BLA for r/r MM accepted by the NMPA
Exclusive CD19 binder license agreement signed with Cabaletta Bio

2021

U.S. R&D presence launched

Completed Series C/C+ financing and raised US$88 million
U.S. R&D laboratory commenced operation
IASO120 received NMPA IND approval for r/r B-NHL and r/r B-ALL
Eque-cel received Breakthrough Therapy Designation from NMPA

Platform foundation

2020

Commercial facility commenced operation

First autoimmune disease patient enrolled
Nanjing commercial facility commenced operation
First patient enrolled in eque-cel Phase II trial for r/r MM
Completed Series B financing and raised US$30 million

2019

Eque-cel IND approved

Eque-cel received IND approval from the NMPA for r/r MM
Completed Series A financing and raised US$30 million

2018

Platform foundation built

Proprietary fully human antibody library established
GMP platform established for plasmids, viruses and cells
Partnered with Innovent on BCMA-targeted CAR-T product development

2017

IASO Bio established

IASO Bio established in the PRC as a limited liability company